Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a biopharmaceutical company with a leading role in cystic fibrosis treatment, sank 42.5% last year, according to data from S&P Global Market Intelligence. …
Sank
J P Morgan Chase & Co reissued their buy rating on shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in a research report sent to investors on Tuesday. Over the last week of the month, it was …
Vertex Pharmaceuticals
On 1/29/2013 Vertex Pharmaceuticals Incorporated announced a quarterly dividend of $0.40 with an ex dividend …
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Director Joshua S. Boger sold 6,500 shares of the company’s stock in a transaction that occurred on Thursday, December 29th. The stock was sold at an …
Sells
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s stock has been of interest for both individual …
Vertex Pharmaceuticals Incorporated
It establishes stock sentiment by reviewing news published on different wired channels on a firm. They contemplate on the most impactful sources at regular intervals. Vertex Pharmaceuticals Incorporated …
Vertex Pharmaceuticals Incorporated